TFIP11

Summary

TFIP11 (tuftelin interacting protein 11, HGNC:17165) is a protein-coding gene on chromosome 22q12.1, encoding Tuftelin-interacting protein 11 (Q9UBB9). Involved in pre-mRNA splicing, specifically in spliceosome disassembly during late-stage splicing events. It is a common-essential gene (DepMap: required in 97.2% of cancer cell lines).

This gene encodes a protein component of the spliceosome that promotes the release of the lariat-intron during late-stage splicing through the recruitment of a pre-mRNA splicing factor called DEAH-box helicase 15. The encoded protein contains a G-patch domain, a hallmark of RNA-processing proteins, that binds DEAH-box helicase 15. This protein contains an atypical nuclear localization sequence as well as a nuclear speckle-targeting sequence, enabling it to localize to distinct speckled regions within the cell nucleus. Polymorphisms in this gene are associated with dental caries suggesting a role in amelogenesis. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 24144 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 83 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 97.2% of screened cell lines (common-essential)
• MANE Select transcript: NM_012143

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17165
Approved symbol	TFIP11
Name	tuftelin interacting protein 11
Location	22q12.1
Locus type	gene with protein product
Status	Approved
Aliases	TIP39, DKFZP434B194, Spp382
Ensembl gene	ENSG00000100109
Ensembl biotype	protein_coding
OMIM	612747
Entrez	24144

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 31 protein_coding, 6 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000405938, ENST00000407148, ENST00000407431, ENST00000407690, ENST00000418876, ENST00000420242, ENST00000440258, ENST00000450493, ENST00000455080, ENST00000464449, ENST00000472918, ENST00000479489, ENST00000481357, ENST00000492137, ENST00000493698, ENST00000496523, ENST00000619735, ENST00000884979, ENST00000884980, ENST00000884981, ENST00000884982, ENST00000884983, ENST00000884984, ENST00000884985, ENST00000884986, ENST00000884987, ENST00000884988, ENST00000916794, ENST00000916795, ENST00000916796, ENST00000916797, ENST00000916798, ENST00000942802, ENST00000942803, ENST00000942804, ENST00000942805, ENST00000942806, ENST00000942807

RefSeq mRNA: 7 — MANE Select: NM_012143 NM_001008697, NM_001346857, NM_001346858, NM_001346859, NM_001346861, NM_001346862, NM_012143

CCDS: CCDS13838

Canonical transcript exons

ENST00000407690 — 15 exons

Exon	Start	End
ENSE00001550432	26510617	26510702
ENSE00001561838	26512099	26512175
ENSE00001651498	26494797	26494939
ENSE00001697569	26496073	26496316
ENSE00001712875	26494139	26494304
ENSE00001739642	26506303	26506459
ENSE00001779090	26496721	26496889
ENSE00001787916	26498869	26498975
ENSE00002203493	26499104	26499631
ENSE00002278996	26506775	26506928
ENSE00003527942	26501900	26502052
ENSE00003593385	26503666	26503793
ENSE00003661808	26510064	26510281
ENSE00003843792	26491240	26492368
ENSE00003847340	26512394	26512473

Expression profiles

Bgee: expression breadth ubiquitous, 267 present calls, max score 93.41.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.5476 / max 183.1792, expressed in 1814 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
193426	17.4963	1814
193425	0.0514	20

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	93.41	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.20	gold quality
gastrocnemius	UBERON:0001388	91.47	gold quality
muscle of leg	UBERON:0001383	91.36	gold quality
apex of heart	UBERON:0002098	91.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	91.03	gold quality
tendon of biceps brachii	UBERON:0008188	90.83	gold quality
sural nerve	UBERON:0015488	90.80	gold quality
left testis	UBERON:0004533	90.66	gold quality
calcaneal tendon	UBERON:0003701	90.43	gold quality
right testis	UBERON:0004534	90.07	gold quality
blood	UBERON:0000178	90.03	gold quality
testis	UBERON:0000473	89.73	gold quality
right lobe of liver	UBERON:0001114	89.70	gold quality
tendon	UBERON:0000043	89.63	gold quality
islet of Langerhans	UBERON:0000006	89.27	gold quality
amniotic fluid	UBERON:0000173	89.14	gold quality
muscle organ	UBERON:0001630	89.13	gold quality
skin of leg	UBERON:0001511	88.85	gold quality
ventricular zone	UBERON:0003053	88.73	gold quality
mucosa of transverse colon	UBERON:0004991	88.66	gold quality
right lobe of thyroid gland	UBERON:0001119	88.61	gold quality
skin of abdomen	UBERON:0001416	88.48	gold quality
stromal cell of endometrium	CL:0002255	88.34	gold quality
ganglionic eminence	UBERON:0004023	88.26	gold quality
body of pancreas	UBERON:0001150	88.14	gold quality
spleen	UBERON:0002106	88.02	gold quality
cortical plate	UBERON:0005343	87.89	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.88	gold quality
left lobe of thyroid gland	UBERON:0001120	87.80	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.01
E-MTAB-6142	no	173.21

Regulation

Is transcription factor: no

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 97.2% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 9)

• TFIP11 is a novel splicing factor and transfected TFIP11-GFP fusion protein was found to locate in a novel subnuclear TFIP body. (PMID:15868102)
• These data help define the mechanism of nuclear/nuclear speckle localization of the splicing factor TFIP11, with implications for it’s function. (PMID:19857462)
• Associations between TFIP11 (p=0.02), ENAM (p=0.00001), and AMELX (p=0.01) could be seen with caries independent of having MIH or genomic DNA copies of Streptococcus mutans detected by real time PCR in the Brazilian sample. (PMID:23790503)
• the statistically significant association of rs2337359 upstream of TUFT1 with dental caries experience via meta-analysis across adult samples (p < 0.002) and the suggestive association for multiple variants in TFIP11 across child samples (PMID:25373699)
• Results suggest that Sip1/tuftelin-interacting protein (STIP, also referred to as TFIP11) may be a novel potential diagnostic and therapeutic target for non-small cell lung cancer (NSCLC). (PMID:26354852)
• We now report the identification of a novel molecular function of STIP that links USP7 to the p53-Mdm2 pathway (PMID:26460617)
• the high expression and activation effect on the ERK1/2 signaling of STIP in lymphoblastic leukemia suggest that STIP would be a potential therapy target or diagnosis marker for leukemia. (PMID:27758712)
• DHX15-independent roles for TFIP11 in U6 snRNA modification, U4/U6.U5 tri-snRNP assembly and pre-mRNA splicing fidelity. (PMID:34789764)
• TFIP11 promotes replication fork reversal to preserve genome stability. (PMID:38341452)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tfip11	ENSDARG00000056932
mus_musculus	Tfip11	ENSMUSG00000029345
rattus_norvegicus	Tfip11	ENSRNOG00000000663
drosophila_melanogaster	sip1	FBGN0024191
caenorhabditis_elegans		WBGENE00007412

Paralogs (2): ZGPAT (ENSG00000197114), LIME1 (ENSG00000203896)

Protein

Protein identifiers

Tuftelin-interacting protein 11 — Q9UBB9 (reviewed: Q9UBB9)

Alternative names: Septin and tuftelin-interacting protein 1

All UniProt accessions (6): Q9UBB9, F6SQZ1, F6UKU9, F6UQ07, F6XM96, H0Y4U8

UniProt curated annotations — full annotation on UniProt →

Function. Involved in pre-mRNA splicing, specifically in spliceosome disassembly during late-stage splicing events. Intron turnover seems to proceed through reactions in two lariat-intron associated complexes termed Intron Large (IL) and Intron Small (IS). In cooperation with DHX15 seems to mediate the transition of the U2, U5 and U6 snRNP-containing IL complex to the snRNP-free IS complex leading to efficient debranching and turnover of excised introns. May play a role in the differentiation of ameloblasts and odontoblasts or in the forming of the enamel extracellular matrix.

Subunit / interactions. Identified in the spliceosome C complex. Found in the Intron Large (IL) complex, a post-mRNA release spliceosomal complex containing the excised intron, U2, U5 and U6 snRNPs, and splicing factors. Interacts with TUFT1. Interacts with DHX15; indicative for a recruitment of DHX15 to the IL complex. Interacts with GCFC2.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the TFP11/STIP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UBB9-1	1	yes
Q9UBB9-2	2

RefSeq proteins (7): NP_001008697, NP_001333786, NP_001333787, NP_001333788, NP_001333790, NP_001333791, NP_036275* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000467	G_patch_dom	Domain
IPR022159	STIP/TFIP11_N	Domain
IPR022783	GCFC_dom	Domain
IPR024933	TFP11	Family
IPR045211	TFP11/STIP/Ntr1	Family

Pfam: PF01585, PF07842, PF12457

UniProt features (22 total): region of interest 6, compositionally biased region 5, modified residue 5, splice variant 2, chain 1, domain 1, sequence variant 1, short sequence motif 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8RO2	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBB9-F1	74.68	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 2, 59, 98, 144, 210

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway
R-HSA-72172	mRNA Splicing
R-HSA-72203	Processing of Capped Intron-Containing Pre-mRNA
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 156 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, GOBP_CHROMOSOME_ORGANIZATION, GOBP_TELOMERE_CAPPING, GOBP_NEGATIVE_REGULATION_OF_DNA_REPAIR, GOBP_TELOMERE_ORGANIZATION, MEF2_02, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_REGULATION_OF_DNA_REPAIR, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, OCT1_03, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, BACH2_01, GOBP_REGULATION_OF_RESPONSE_TO_STRESS

GO Biological Process (9): spliceosomal complex disassembly (GO:0000390), mRNA splicing, via spliceosome (GO:0000398), RNA processing (GO:0006396), biomineral tissue development (GO:0031214), negative regulation of protein-containing complex assembly (GO:0031333), protection from non-homologous end joining at telomere (GO:0031848), negative regulation of double-strand break repair via nonhomologous end joining (GO:2001033), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (2): nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (10): chromosome, telomeric region (GO:0000781), nucleoplasm (GO:0005654), spliceosomal complex (GO:0005681), nucleolus (GO:0005730), cytoplasm (GO:0005737), nuclear speck (GO:0016607), extracellular matrix (GO:0031012), U2-type post-mRNA release spliceosomal complex (GO:0071008), catalytic step 2 spliceosome (GO:0071013), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
mRNA Splicing	1
Processing of Capped Intron-Containing Pre-mRNA	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
binding	2
nuclear lumen	2
cellular anatomical structure	2
mRNA splicing, via spliceosome	1
protein-RNA complex disassembly	1
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
tissue development	1
animal organ development	1
regulation of protein-containing complex assembly	1
negative regulation of cellular component organization	1
protein-containing complex assembly	1
telomere capping	1
telomere maintenance in response to DNA damage	1
double-strand break repair via nonhomologous end joining	1
negative regulation of double-strand break repair	1
regulation of double-strand break repair via nonhomologous end joining	1
mRNA metabolic process	1
chromosomal region	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
nuclear ribonucleoprotein granule	1
external encapsulating structure	1
U2-type spliceosomal complex	1
U6 snRNP	1
post-mRNA release spliceosomal complex	1
Prp19 complex	1
spliceosomal complex	1
U5 snRNP	1
catalytic complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2666 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TFIP11	DHX15	O43143	994
TFIP11	TUFT1	Q9NNX1	979
TFIP11	NTSR2	O95665	958
TFIP11	CWC25	Q9NXE8	724
TFIP11	SLU7	O95391	708
TFIP11	SRSF2	Q01130	688
TFIP11	AMBN	Q9NP70	668
TFIP11	ENAM	Q9NRM1	666
TFIP11	EFTUD2	Q15029	654
TFIP11	GPATCH2	Q9NW75	653
TFIP11	GCFC2	P16383	650
TFIP11	DHX8	Q14562	616
TFIP11	SNRPA1	P09661	612
TFIP11	SF3A1	Q15459	602
TFIP11	DHX38	Q92620	596

IntAct

1061 interactions, top by confidence:

A	B	Type	Score
TFIP11	PRPF31	psi-mi:“MI:0915”(physical association)	0.890
PRPF31	TFIP11	psi-mi:“MI:0915”(physical association)	0.890
COQ8A	TFIP11	psi-mi:“MI:0915”(physical association)	0.850
TFIP11	COQ8A	psi-mi:“MI:0915”(physical association)	0.850
FAM161A	TFIP11	psi-mi:“MI:0915”(physical association)	0.840
SNW1	TFIP11	psi-mi:“MI:0915”(physical association)	0.830
PBX4	TFIP11	psi-mi:“MI:0915”(physical association)	0.830
TFIP11	SNW1	psi-mi:“MI:0915”(physical association)	0.830
TFIP11	PBX4	psi-mi:“MI:0915”(physical association)	0.830
TFIP11	ZGPAT	psi-mi:“MI:0915”(physical association)	0.810
TFIP11	KRT6A	psi-mi:“MI:0915”(physical association)	0.790
CCHCR1	TFIP11	psi-mi:“MI:0915”(physical association)	0.790
TSHZ3	TFIP11	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	LMO1	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	KRT20	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	TXLNA	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	GEM	psi-mi:“MI:0915”(physical association)	0.780
CCDC121	TFIP11	psi-mi:“MI:0915”(physical association)	0.780
SMARCE1	TFIP11	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	BMF	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	THAP7	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	CCDC68	psi-mi:“MI:0915”(physical association)	0.780
TFIP11	SH2D4A	psi-mi:“MI:0915”(physical association)	0.780

BioGRID (583): TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid), TFIP11 (Two-hybrid)

ESM2 similar proteins: A0JMA8, A1XD93, A1XD94, A1XD95, A1XD97, A4UMC5, A4UMC6, B3DJT0, B5DFC8, E7EXT2, E7F187, F1M3L7, F7AEX0, O14617, O54774, P52590, P53569, P57740, P78344, P79398, Q06AK6, Q0IIX9, Q12929, Q17784, Q17CQ8, Q29RR5, Q2KI89, Q5R4H4, Q5R5K8, Q5R629, Q5R7J9, Q5TYV4, Q5U2Y6, Q5ZII9, Q62448, Q66J74, Q6DI35, Q865S1, Q8BH74, Q8IQ05

Diamond homologs: A1XD93, A1XD94, A1XD95, A1XD97, A4UMC5, A4UMC6, A7SBN6, B3MPC0, B3N8L3, B4G7U3, B4HWD7, B4JCG4, B4KH32, B4M9F7, B4NYQ2, B4Q8A7, C0HAV3, C5IJB0, P10265, P63119, P63121, P63123, P63124, P63125, P63129, P63131, P70501, P98175, Q06411, Q06AK6, Q0IIX9, Q17784, Q17CQ8, Q17QX2, Q28H71, Q29NF3, Q29RR5, Q5PPF5, Q5R5K8, Q5U2Y6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1378 predictions. Top by Δscore:

Variant	Effect	Δscore
22:26491541:T:A	acceptor_gain	1.0000
22:26492367:ACC:A	acceptor_loss	1.0000
22:26492368:CCTA:C	acceptor_loss	1.0000
22:26492369:CTAAG:C	acceptor_loss	1.0000
22:26494135:TTA:T	donor_loss	1.0000
22:26494136:TA:T	donor_loss	1.0000
22:26494136:TACCA:T	donor_gain	1.0000
22:26494137:A:AC	donor_gain	1.0000
22:26494137:A:C	donor_loss	1.0000
22:26494137:ACCAA:A	donor_gain	1.0000
22:26494138:C:CC	donor_gain	1.0000
22:26494138:CCA:C	donor_gain	1.0000
22:26494138:CCAA:C	donor_gain	1.0000
22:26494138:CCAAC:C	donor_gain	1.0000
22:26494300:AGCAC:A	acceptor_gain	1.0000
22:26494302:CAC:C	acceptor_gain	1.0000
22:26494303:ACCT:A	acceptor_loss	1.0000
22:26494305:C:CC	acceptor_gain	1.0000
22:26494306:T:C	acceptor_loss	1.0000
22:26496067:CCTTA:C	donor_loss	1.0000
22:26496068:CTTA:C	donor_loss	1.0000
22:26496069:TTA:T	donor_loss	1.0000
22:26496070:TACCC:T	donor_loss	1.0000
22:26496071:A:C	donor_loss	1.0000
22:26496071:AC:A	donor_gain	1.0000
22:26496072:C:CA	donor_loss	1.0000
22:26496072:CC:C	donor_gain	1.0000
22:26496072:CCCAG:C	donor_gain	1.0000
22:26496076:G:C	donor_gain	1.0000
22:26496108:T:TA	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000030080 (22:26512433 C>A), RS1000265701 (22:26501371 A>C), RS1000331793 (22:26506954 C>A,T), RS1000429304 (22:26500915 G>A,T), RS1000461734 (22:26501128 G>A,C), RS1000597978 (22:26502699 C>G), RS1000667492 (22:26496374 C>G), RS1000709359 (22:26495679 T>C), RS1000798365 (22:26502522 G>A), RS1000827551 (22:26509356 C>A), RS1001048350 (22:26497122 C>G,T), RS1001757909 (22:26506607 G>A), RS1002085444 (22:26501561 T>C,G), RS1002090257 (22:26507911 G>A), RS1002458879 (22:26493045 A>G)

Disease associations

OMIM: gene MIM:612747 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724604 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.17	Kd	67	nM	MOLIBRESIB
7.10	IC50	80	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179092: Binding affinity against TFIP11 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0670	uM

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, increases methylation	2
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
sodium arsenite	increases expression	1
tobacco tar	increases expression	1
coumarin	affects phosphorylation	1
cupric oxide	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
M-VAC protocol	decreases response to substance	1
beta-methylcholine	affects expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	increases expression	1
Zoledronic Acid	decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Cadmium	increases abundance, increases expression	1
Caffeine	decreases phosphorylation	1
Copper	affects binding, decreases expression	1
Diazinon	increases methylation	1
Disulfiram	affects binding, decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Rotenone	decreases expression	1
Dronabinol	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	affects expression	1
Cadmium Chloride	increases abundance, increases expression	1
Copper Sulfate	increases expression	1
Volatile Organic Compounds	affects cotreatment, increases oxidation	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697127	Binding	Inhibition of TFIP11 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.